Open AccessHigh Incidence of Herpes Zoster After Cord Blood Hematopoietic Cell Transplant Despite Longer Duration of Antiviral Prophylaxis
Author(s) -
Elisabetta Xue,
Hu Xie,
Wendy Leisenring,
Louise E. Kimball,
Sonia Goyal,
Lisa Chung,
Rachel Blazevic,
Byron Maltez,
A. S. Edwards,
Ann Dahlberg,
Rachel B. Salit,
Colleen Delaney,
Steven A. Pergam,
Michael Boeckh,
Filippo Milano,
Joshua A. Hill
Publication year - 2020
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa222
Subject(s) - medicine , cumulative incidence , incidence (geometry) , hazard ratio , confidence interval , context (archaeology) , proportional hazards model , cohort , hematopoietic cell , varicella zoster virus , surgery , immunology , virus , haematopoiesis , paleontology , physics , optics , biology , genetics , stem cell
Cord blood transplant (CBT) recipients have a high incidence of herpes zoster (HZ) in the context of short-term peritransplant antiviral prophylaxis. In 2009, international guidelines recommended HZ prophylaxis for at least 1 year after hematopoietic cell transplant. The impact of longer-term antiviral prophylaxis on HZ incidence after CBT is unknown.